Studying how male hormones affect the immune environment in glioblastoma
Collects blood, saliva, stool and tumor samples from adults with glioblastoma.
Plain-language title generated from the registry record
Registry title: Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas
Key facts
- Where
- Paris, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07472387, who can take part
Where in France
- Neuro-oncology department, Pitié Salpêtrière hospitalParis, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07472387
- Record updated
- 16 March 2026
- Original description
Glioblastoma (GBM) is the most common and most aggressive primary brain cancer in adults. GBM is more common in men than in women, with a male-to-female ratio of 1.6. Furthermore, being male is associated with a poorer prognosis. These data suggest that sex and/or sexual hormones and more specifically androgens may play a role in the initiation, the growth, and the resistance to treatments of GBM.Read full original descriptionShow less
Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas
Glioblastoma (GBM) is the most common and most aggressive primary brain cancer in adults. GBM is more common in men than in women, with a male-to-female ratio of 1.6. Furthermore, being male is associated with a poorer prognosis. These data suggest that sex and/or sexual hormones and more specifically androgens may play a role in the initiation, the growth, and the resistance to treatments of GBM.
Inclusion: Patients aged ≥18 and ≤55; Newly diagnosed GBM; Surgery with complete or incomplete resection; Eligible for chemoradiotherapy; No active immune disorders; Supratentorial location on MRI and no signs of meningeal dissemination; Tumor sample (taken as part of treatment) available for study (fresh frozen tissue); Patient informed and consented to participate in the study; Affiliation with a social security system or beneficiary.
Exclusion: Active infection at the time of sampling or within the previous 14 days; Patients treated with corticosteroids; Active immune disorders; Known patients with low-grade glioma that has undergone anaplastic transformation; Patients participating in interventional research; Patients under legal protection, guardianship, or conservatorship; Pregnant or breastfeeding women; Individuals under AME.